<DOC>
	<DOCNO>NCT00002125</DOCNO>
	<brief_summary>To assess relative efficacy oral versus intravenous hydration foscarnet sodium ( Foscavir ) induction therapy , determine change creatinine clearance . To estimate timing volume oral fluid hydration require establish diuresis intravenous Foscavir therapy . To assess general tolerance two hydration regimen adverse event profile associate .</brief_summary>
	<brief_title>A Multicenter Study Oral Versus Intravenous Hydration AIDS Patients With CMV Retinitis Treated With Foscavir ( Foscarnet Sodium )</brief_title>
	<detailed_description>Patients randomize receive oral hydration versus intravenous hydration therapy concomitant intermittent intravenous Foscavir therapy treatment cytomegalovirus ( CMV ) retinitis . Treatment continue 2 3 week induction Foscavir therapy .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . Recent diagnosis CMV retinitis , ophthalmoscopic appearance , require induction therapy . No corneal , lens , vitreous opacification precludes examination fundus . No evidence end organ CMV infection . No evidence tuberculous , diabetic , hypertensive retinopathy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Clinically significant cardiac , pulmonary , neurologic , gastrointestinal renal impairment would prevent adequate voluntary oral hydration ( e.g. , intubation , coma , status postgastrectomy , colon resection , gastrointestinal tumor , malabsorption , chronic diarrhea ) OR hydration would hazardous ( e.g. , congestive heart failure ) . Known allergy foscarnet relate compound . Considered noncompliant unreliable study participation . Concurrent Medication : Excluded : Any investigational drug . Potentially nephrotoxic drug ( e.g. , amphotericin B , aminoglycosides , cisplatin ) . Prior Medication : Excluded : Any investigational drug within 28 day prior study entry . Potentially nephrotoxic drug ( e.g. , amphotericin B , aminoglycosides , cisplatin ) within 7 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1997</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Administration , Oral</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Fluid Therapy</keyword>
</DOC>